A Noninterventional Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Practice
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 May 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms CIMAX
- Sponsors UCB
- 13 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Jun 2016 Planned End Date changed from 1 Nov 2017 to 1 Mar 2018.
- 03 Jun 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Mar 2018.